Our Collaborators

In June 2019, SpringWorks entered into a clinical collaboration with GlaxoSmithKline to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate, BLENREP (belantamab mafodotin), in patients with relapsed or refractory multiple myeloma. Read more

In January 2020, SpringWorks entered into a clinical collaboration with Allogene Therapeutics to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Allogene’s investigational BCMA AlloCAR TTM therapy in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a clinical collaboration with Janssen Biotech, Inc. to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Janssen’s investigational BCMA CD3 bispecific antibody, teclistamab, in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a clinical collaboration with Precision BioSciences to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat, in combination with Precision BioSciences’ investigational BCMA allogeneic CAR T cell therapy, PBCAR269A, in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center to further evaluate nirogacestat’s ability to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch. Read more

In October 2020, SpringWorks entered into a clinical collaboration with Pfizer to conduct a Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Pfizer’s investigational BCMA CD3 bispecific antibody, elranatamab, in patients with relapsed or refractory multiple myeloma. Read more

In June 2021, SpringWorks entered into a clinical collaboration with Seagen to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Seagen’s investigational monoclonal antibody, SEA-BCMA, in patients with relapsed or refractory multiple myeloma. Read more

In August 2021, SpringWorks entered into a sponsored research collaboration with the Dana-Farber Cancer Institute to further evaluate nirogacestat’s ability to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical multiple myeloma models. Read more

In August 2018, SpringWorks entered into a clinical collaboration with BeiGene to evaluate the safety, tolerability, and preliminary efficacy of BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283), in combination with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. Read more

In June 2019, SpringWorks and BeiGene announced the formation of MapKure, a clinical-stage company developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating BRAF mutations, including V600 BRAF mutations, non-V600 BRAF mutations and RAF fusions. Read more

In December 2020, SpringWorks entered into a research collaboration agreement with the University of Eastern Finland to conduct novel computational biology research to characterize the effector protein dynamics of different RAS mutations. The objective of the collaboration is to understand the biological consequences of KRAS-effector protein interactions and downstream oncogenic signaling with the goal of guiding patient selection strategies and exploring novel targets for future targeted therapy development.

In March 2021, SpringWorks entered into a research collaboration agreement with Inserm Transfert, acting as a delegate of the French National Institute of Health and Medical Research (Inserm) to explore the ability of nirogacestat to delay the development of resistance to the EGFR inhibitor osimertinib in preclinical models of non-small cell lung cancer (NSCLC) driven by the EGFR C797S gatekeeper mutation.

In May 2021, SpringWorks entered into a research collaboration with the University of Zurich to further explore the activity of mirdametinib and lifirafenib combination therapy in preclinical patient-derived NRAS-mutant in vitro and in vivo solid tumor models.

In August 2021, SpringWorks entered into a collaboration with Memorial Sloan Kettering Cancer Center to conduct a Phase 1b/2a study to evaluate mirdametinib in combination with fulvestrant, a selective estrogen receptor degrader (SERD), in postmenopausal patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) harboring NF1 loss-of-function or other alterations of the MAPK pathway, and as a monotherapy in adult patients with advanced solid cancers harboring MEK1 or MEK2 mutations. Read more

In September 2020, SpringWorks entered into a collaboration with the Children’s Oncology Group to conduct a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors. Read more

In June 2021, SpringWorks entered into a collaboration with the St. Jude Children’s Research Hospital to conduct a Phase 1/2 clinical trial evaluating mirdametinib in children, adolescents, and young adults with low-grade glioma.